外部評価のコ� �ントとコメン� ��への対応（PDF ファイル／139KB ）.pdf

The guideline for alleviating gastrointestinal symptoms in cancer patients has been externally evaluated, and the comments are summarized as follows:

The guideline has been revised to include new items such as abdominal fluid and constipation, making it more useful for members.
The chapter on non-pharmacological therapy is well-written and easy to understand, but some evaluators suggest that it should be combined with the chapter on pharmacological therapy.
Some evaluators point out that the evidence level of the guideline is not high, and that some contents are more like a textbook than a guideline.
The guideline lacks a clear structure, and some evaluators suggest that the chapters should be reorganized to make it easier to follow.
Some evaluators suggest that the guideline should include more information on the use of naldeemedin, a peripheral μ-opioid receptor antagonist.
The guideline has been revised to include more information on the use of linacotide and naldeemedin for constipation.
Some evaluators point out that the guideline lacks information on the use of certain medications, such as octreotide, and that the dosage of some medications, such as olanzapine, is not clear.
The guideline has been revised to include more information on the use of octreotide and to clarify the dosage of olanzapine.

Overall, the evaluators suggest that the guideline is well-written and easy to understand, but that it needs to be revised to include more information on certain topics and to clarify some of the contents.